Analytical Data
-
Gene name
NAP-2/CXCL7
- Application
-
Alternative Names
CXCL7; PPBP; PBP; B-TG1; CTAP-III; CTAP3; CTAPIII; LA-PF4; LDGF; MDGF; NAP2; SCYB7; TC1; TC2; TGB1; THBGB1; Pro-Platelet Basic Protein; Beta-Thromboglobulin
-
Species
Mouse
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 97% as determined by SDS-PAGE.
-
Uniprot
Q9EQI5
-
Expression Region
Lys40~Tyr113
-
Protein Length
Partial
-
Molecular Weight
11kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NAP-2, also known as CXCL7, is a member of the CXC chemokine family and plays a crucial role in immune responses and inflammation. This chemokine is primarily produced by platelets and various immune cells, where it functions as a potent chemotactic factor, attracting neutrophils and other inflammatory cells to sites of injury or infection. Recent studies have highlighted its involvement in various pathological conditions, including cancer, atherosclerosis, and autoimmune diseases, suggesting that NAP-2/CXCL7 could serve as both a biomarker and a therapeutic target. Due to its significant role in modulating immune cell activity, researchers have focused on the production and characterization of recombinant NAP-2/CXCL7 protein to further understand its biological functions and mechanisms. Recombining this protein allows for the exploration of its effects on cell signaling pathways, migration, and activation of immune responses. Additionally, developing recombinant NAP-2/CXCL7 can facilitate high-throughput drug screening and the discovery of novel therapeutic agents aiming to modulate its activity for potential clinical applications. Overall, this research background highlights the importance of NAP-2/CXCL7 in both basic and translational immunology, paving the way for future studies that could lead to new treatments for inflammation-related disorders.
